Aequs Limited (AEQUS)
Investor Presentation
Investor Presentation - Q2 & H1 FY27
- Revenue grew 50% YoY to ₹8,046 Mn in H1 FY27; Q2 revenue ₹4,091 Mn +45% YoY
- Aerospace revenue up 42% YoY; Consumer revenue more than doubled YoY
- Aerospace order book at USD 1,096 Mn with long-term contracts including Safran A320 wheels
- Consumer segment ramp delayed due to qualification and supply constraints; EBITDA breakeven path recalibrated
- Capital expenditure ₹1,597 Mn in H1 FY27; ₹6,500 Mn promoter warrant to support expansion
- New CFO appointed; strengthened Safran partnerships expanding manufacturing scope
- Aerospace capacity utilisation at 76%, Consumer at 17% in Q2 FY27
- Net loss ₹(1,054) Mn in H1 FY27 due to expensed consumer electronics costs
- Focus on utilisation improvement and profitable growth in Consumer segment
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 AEQUS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add AEQUS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Aequs Limited
Important.
The summary above is generated automatically from Aequs Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.